Skip to Content


Explore our Regulatory Affairs & Operations Services

Step into the forefront of Regulatory Affairs & Operations excellence with Halloran, where cutting-edge solutions redefine industry standards. Our streamlined approach prioritizes precision in regulatory compliance, optimizing every facet from strategy development to operational execution. Dive into data-driven insights that empower informed decisions, offering a comprehensive understanding of regulatory intricacies. Forge collaborative partnerships with a dedicated team, overcoming challenges and achieving milestones that set new benchmarks in regulatory affairs. Trust in our reliability at every stage, where accuracy, compliance, and security ensure the integrity of your regulatory data. Elevate your regulatory potential with Halloran’s tailored solutions, pioneering the future of excellence in regulatory affairs and operations. Ready to redefine industry standards? Explore Halloran today, where innovation and regulatory expertise converge to open doors to boundless possibilities!


  • This comprehensive webinar offers an insightful exploration into the intricate landscape of New Drug Applications (NDAs) and Biologics License Applications (BLAs), elucidating the pivotal regulatory procedures imperative for pharmaceutical companies seeking approval for novel drugs and biologics. Its primary objective is to equip participants with the requisite knowledge and resources essential for navigating the intricate […]

  • In vitro diagnostic (IVD) devices are a unique type of medical device. Although they meet the definition of a medical device, they are not intended to treat a disease or condition. Rather, they are the instruments or reagents that analyze samples taken from patients. IVDs are less invasive than traditional medical devices, but still present […]

  • On September 29, 2023, the U.S. Food and Drug Administration (FDA) took action to help further accelerate the development of novel drug and biological products for rare diseases. The action, an announcement of an opportunity for a limited number of sponsors to participate in a pilot program (Support for Clinical Trials Advancing Rare Disease Therapeutics […]